A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: CBS News
In 2019, a genetic therapy was approved by the Food and Drug Administration to treat SMA, but the single-dose therapy costs $2 million. Green's insurance said it wouldn't pay for the new, expensive drug. "I became very angry, to know that there was something that could help her. And I knew without a shadow of a doubt I was burying my daughter before she was 2," Green said. The Zolgensma medication Maisie needed is part of a new breakthrough class of gene therapies often treating rare diseases where patients have few, if any options. But, as the high-cost drugs treat more common diseases, they could have wider impacts on the U.S. health care system. "I liken it to a coming tsunami, which is basically gonna overwhelm the employer-sponsored insurance system," said economist Jonathan Gruber, who helped develop the Affordable Care Act. Today, more than 300 high-cost genetic therapies are in clinical trials, and some are aimed to treat diseases suffered by millions. Companies who pr
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]CBS News
- Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027Business Wire
- Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.MarketBeat
- Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness Wire
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 12/11/25 - Form 8-K
- 12/10/25 - Form 4
- 12/9/25 - Form 4
- SRPT's page on the SEC website